Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;52(11):1222-1227.
doi: 10.1016/j.dld.2020.09.002. Epub 2020 Sep 6.

COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data

Fabio Salvatore Macaluso  1 , Ambrogio Orlando  2
Affiliations

COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data

Fabio Salvatore Macaluso et al. Dig Liver Dis. 2020 Nov.

Abstract

Background: Great efforts by the scientific community are rapidly expanding the evidence on the clinical interplay between Covid-19 and inflammatory bowel disease (IBD).

Aims: We performed a systematic review of the literature on published Covid-19 cases occurring in patients with IBD.

Methods: PubMed Central/Medline and Embase were systemically searched for records up to May 31, 2020.

Results: 13 cohort studies and 5 single case reports were included in the qualitative synthesis. A cumulative number of approximately 800 patients with IBD and Covid-19 were identified. The case fatality rate ranged from 0% to 20.0%. Overall, immunomodulators and biologics were not associated with higher risk of Covid-19 or with negative outcomes, while the use of systemic corticosteroids was related to worse prognosis in some studies.

Conclusions: This systematic review highlighted two main points that may help clinicians dealing with IBD in reassuring their patients: (1) patients with IBD do not seem to be at higher risk of being infected by SARS-COV-2 than the general population; (2) in case of Covid-19, treatment with immunomodulators or biologics is not associated with worse prognosis, while systemic steroids are suspected to be potentially detrimental, even if more data are needed to confirm this point.

Keywords: Biologics; Covid-19; Immunomodulators; Sars-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of the search process. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

References

    1. Zhu N., Zhang D., Wang W., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Symptoms of coronavirus disease2019 (COVID–19). 2020 (https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html).
    1. World Health Organization. Rolling updates on coronavirus disease (COVID-19). 2020 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-a...).
    1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report — 132. May 31, 2020. (https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...).
    1. Stroup D.F., Berlin J.A., Morton S.C., et al. for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of Observational Studies in Epidemiology. A Proposal for Reporting. JAMA. 2000;283:2008–2012. - PubMed

Publication types

Substances

LinkOut - more resources